KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) reported positive topline results from the Phase 3 KEYNOTE-859 trial investigating KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. In the trial, KEYTRUDA in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival versus chemotherapy alone in the all-randomized patient population at a pre-specified interim analysis conducted by an independent Data Monitoring Committee. Statistically significant and clinically meaningful improvements in progression-free survival and overall response rate were also observed. The safety profile was consistent with that observed in previously reported studies.
'The results from KEYNOTE-859 show the potential of KEYTRUDA plus chemotherapy to improve survival beyond chemotherapy alone for patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression,' said Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.
For More Such Health News, visit rttnews.com.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News
